Seeking Alpha

The European Commission amends the marketing authorization for Celgene's (CELG -0.2%) REVLIMID...

The European Commission amends the marketing authorization for Celgene's (CELG -0.2%) REVLIMID to include patients with MDS-related transfusion-dependent anemia when other treatments have failed or proven insufficient. The company has pursued clearance for the indication for some 7 years. (previous)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector